Julie Grisham

Chicago

Science and Medical Writer at Freelance

I don't know what to say... Ha! I always know what to say.

Featured in: Favicon

scientificamerican.com Favicon

medicalxpress.com Favicon

emory.edu

geneticliteracyproject.org Favicon

scitechdaily.com Favicon

curetoday.com Favicon

elsevier.com Favicon

knowridge.com Favicon

mskcc.org

news.emory.edu

Articles

MSK Researchers Present Advances in Lung Cancer Treatment at 2025 ASCO Meeting

1 week ago | mskcc.org | Julie Grisham

Researchers from Memorial Sloan Kettering Cancer Center (MSK) reported important advances in the treatment of lung cancer at the annual meeting of the American Society of Clinical Oncology (ASCO), held May 30 to June 3 in Chicago. Scientists presented promising results on three different targeted therapies — one for small cell lung cancer and two for non-small cell lung cancer.
MSK’s 2025 Convocation Inspires and Honors Achievement

3 weeks ago | mskcc.org | Julie Grisham

Memorial Sloan Kettering Cancer Center (MSK) celebrated new graduates and award winners at the Academic Convocation and Commencement, held on May 14. In 2025, 14 students earned their doctoral degrees in cancer biology from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) — the educational division of MSK. In addition, two practicing MSK doctors received Master of Science degrees in clinical and translational cancer research from GSK.
FDA Approves Avutometinib-Defactinib Combination for Treating Recurrent Low-Grade Serous Ovarian Cancer With a KRAS Mutation

3 weeks ago | mskcc.org | Julie Grisham

The first drug for a rare and difficult-to-treat type of ovarian cancer has been granted accelerated approval by the Food and Drug Administration (FDA). The treatment, called avutometinib plus defactinib (Avmapki Fakzynja Co-pack), was developed to treat low-grade serous ovarian cancer (LGSOC). The phase 2 clinical trial that resulted in the approval was led in the United States by gynecologic medical oncologist Rachel Grisham, MD, of Memorial Sloan Kettering Cancer Center (MSK).
Meet the 2025 Graduates of the Gerstner Sloan Kettering Graduate School

1 month ago | mskcc.org | Julie Grisham

I conducted my dissertation research in the laboratory of John Maciejowski, PhD, whose work centers on cytosolic DNA sensing and innate immune signaling in chromosomally unstable cancers. These cancers frequently exhibit mitotic errors, leading to the formation of micronuclei — small, aberrant nuclear structures that encapsulate mis-segregated chromosomes or chromosomal fragments. Due to their fragile nuclear envelopes, micronuclei are prone to spontaneous rupture, exposing DNA to the cytosol.
Why Clonal Hematopoiesis, a Blood Condition Related to Aging, Is Linked to Worse Outcomes for Cancer Patients

1 month ago | mskcc.org | Julie Grisham

Doctors and scientists have known for nearly a decade that a precancerous blood condition called clonal hematopoiesis (CH) is present in one in three patients with solid tumors and is associated with poor cancer outcomes. People with CH are less likely to respond to treatment and are more likely to develop a secondary leukemia related to chemotherapy.
Potential New Treatment for KRAS-GI2D Lung Cancer Reported in First-of-Its-Kind Clinical Trial

1 month ago | mskcc.org | Julie Grisham

For decades, cancers with mutations in the gene KRAS (KAY-ras) were considered “undruggable.” KRAS mutations are found in more than 20% of cancers. They are most common in lung cancer, pancreatic cancer, and colorectal cancer. Nearly four years ago, the first drug was approved to treat patients with one subtype of KRAS mutation. But there are many other subtypes, and it’s possible that targeting each one may require its own strategy.
A New Cellular Immunotherapy Approach May Offer Treatment for AML and MDS

1 month ago | mskcc.org | Julie Grisham

The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging to treat. While advances in immunotherapy have cured many patients with other blood cancers, they haven’t been successful for AML and MDS. Together, these diseases kill thousands of people in the United States every year.
She Couldn’t Afford Metastatic Breast Cancer Treatment: How MSK Helped

2 months ago | mskcc.org | Julie Grisham

It was hard enough for Stephanie Soto-Vega to get the news that her breast cancer had spread to her hip bones and spine. Then came another blow: Her insurance company wouldn’t cover the medication to keep the cancer under control. It cost $15,000 a month. “I was really worried,” remembers Stephanie, who had a new baby named Luna.
Promising New Treatment for Myelofibrosis Blood Cancer Using a Combination Targeted Therapy

2 months ago | mskcc.org | Julie Grisham

An international phase 3 clinical trial of a new drug combination for treating the blood cancer myelofibrosis found that adding a second, experimental drug to standard treatment was more effective than the standard treatment alone. Further, adding the second drug did not significantly increase side effects. Memorial Sloan Kettering Cancer Center (MSK) enrolled the most patients in the trial.
FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumor (TGCT)

Feb 19, 2025 | mskcc.org | Julie Grisham

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that lines the joints. Sarcoma oncologist William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), led the international phase 3 MOTION trial that resulted in the drug’s approval.